Literature DB >> 4810592

Optimization of the ratio of stannous tin: ethane-1-hydroxy-1, 1-diphosphonate for bone scanning with 99mTc-pertechnetate.

A J Tofe, M D Francis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4810592

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  9 in total

1.  Structural characterization of a bridged 99Tc-Sn-dimethylglyoxime complex: implications for the chemistry of 99mTc-radiopharmaceuticals prepared by the Sn (II) reduction of pertechnetate.

Authors:  E Deutsch; R C Elder; B A Lange; M J Vaal; D G Lay
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

2.  Quantitative analysis of the distribution of 99mTc-labelled ethylene hydroxy diphosphonate in young rats.

Authors:  M Rohlin; B Nosslin
Journal:  Eur J Nucl Med       Date:  1977-06-30

3.  Isotope retention for assessment of bone turnover in involutional osteoporosis.

Authors:  M Passeri; E Palummeri; M C Baroni; F Quaini; A Quintavalla; M Barbagallo; D Franchini; D Ugolotti
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

4.  Kinetics of 99mtechnetium-tin-methylene-diphosphonate in normal subjects and pathological conditions: a simple index of bone metabolism.

Authors:  A Caniggia; A Vattimo
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

5.  The clinical role of skeletal scanning.

Authors:  P J Ell
Journal:  Ann R Coll Surg Engl       Date:  1975-12       Impact factor: 1.891

6.  Experimental examinations on the suitability of organoaminomethane-bis-phosphonic acids for bone-scintigraphy by means of Tc-99m in animals.

Authors:  S Unterspann
Journal:  Eur J Nucl Med       Date:  1976-08-12

Review 7.  Skeletal uptake of diphosphonate: a review.

Authors:  I Fogelman
Journal:  Eur J Nucl Med       Date:  1980-12

8.  Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues.

Authors:  M D Francis; C L Slough; A J Tofe
Journal:  Calcif Tissue Res       Date:  1976-06-14

Review 9.  The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain.

Authors:  Giovanni Iolascon; Antimo Moretti
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.